STOCK TITAN

Heartflow’s Campbell Rogers reports 111,412 shares sold

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Heartflow, Inc. (HTFL) Chief Medical Officer Campbell Rogers reported 111,412 shares sold across transactions dated February 20 through November 17, 2026. On November 17, he exercised options for 12,328 shares at $8.33 and 5,101 shares at $2.22. Sales that day included 24,188 directly held shares, 5,654 shares held by Campbell Rogers 2019 Irrevocable Trust, and 6,503 shares held by Spouse's Trust, each at $46.39 per share. Transactions were effected under Rule 10b5-1 plans adopted September 12, 2025, and June 16, 2026. A footnote for the 5,101-share option says it vests and becomes exercisable in monthly installments until July 1, 2027, subject to continued service through the applicable vesting date.

Insider Rogers Campbell
Role Chief Medical Officer
Sold 111,412 shs ($4.22M)
Approx. gross sale proceeds $4.22M
Approx. exercise cost $114K
Share of Position Sold 59.3%
Type Security Shares Price Value
Exercise Stock Option F4, F7 12,328 $0.00 $0.00
Exercise Stock Option F4, F8 5,101 $0.00 $0.00
Exercise Common Stock F4 12,328 $8.33 $103K
Exercise Common Stock F4 5,101 $2.22 $11K
Sale Common Stock F5 24,188 $46.39 $1.12M
Sale Common Stock F6 5,654 $46.39 $262K
Sale Common Stock F3 6,503 $46.39 $302K
Holding Common Stock -- -- --
Sale Common Stock F3 5,654 $55.01 $311K
Sale Common Stock F3 6,503 $55.01 $358K
Sale Common Stock F1 5,653 $50.15 $283K
Sale Common Stock F3 6,503 $50.15 $326K
Sale Common Stock F1 16,918 $24.67 $417K
Sale Common Stock F1 16,918 $25.00 $423K
Sale Common Stock F1, F2 16,918 $24.40 $413K
Holdings After Transaction: Stock Option — 67,380 options (Direct); Common Stock — 0 shares (Indirect, By The Campbell Rogers Revocable Trust); Common Stock — 64,424 shares (Direct); Common Stock — 5,654 shares (Indirect, By Campbell Rogers 2019 Irrevocable Trust); Common Stock — 6,503 shares (Indirect, By Spouse's Trust); Common Stock — 46,159 shares (Indirect, By CR Asset Protection Trust of 2023)
Holdings Before and After: Stock Option, 84,809 to 67,380 options (Direct); Common Stock, 50,754 to 0 shares (Indirect, By The Campbell Rogers Revocable Trust); Common Stock, 71,183 to 64,424 shares (Direct); Common Stock, 22,615 to 5,654 shares (Indirect, By Campbell Rogers 2019 Irrevocable Trust); Common Stock, 26,012 to 6,503 shares (Indirect, By Spouse's Trust)
Other Insiders: 2 other insiders reported open-market sales of this stock in the 30 days up to this filing.
Footnotes (8)
  1. F1. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2025.
  2. F2. This transaction was executed in multiple trades at price ranging from $22.46 to $26.55. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  3. F3. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 16, 2026
  4. F4. The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on June 16, 2026.
  5. F5. Includes the sale of 6,759 shares of common stock held and the option exercise and sale of 17,429 shares reported on this Form 4 that were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on June 16, 2026.
  6. F6. The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on June 16, 2026.
  7. F7. These stock options are fully exercisable.
  8. F8. The option vests and becomes exercisable in monthly installments until July 1, 2027, subject to continued service through the applicable vesting date.
Reported shares sold 111,412 shares Across transactions dated February 20 through November 17, 2026
Options exercised 12,328 shares November 17, 2026; exercise price $8.33 per share
Option exercise price $8.33 per share For options covering 12,328 shares on November 17, 2026
Options exercised 5,101 shares November 17, 2026; exercise price $2.22 per share
Option exercise price $2.22 per share For options covering 5,101 shares on November 17, 2026
Sale price $46.39 per share Sales dated November 17, 2026
Trust holding 46,159 common shares CR Asset Protection Trust of 2023; holding entry dated November 17, 2026
February 20 trust sale 16,918 shares; $24.40 per share The Campbell Rogers Revocable Trust; reported weighted average sale price
Rule 10b5-1 trading plan regulatory
"effected pursuant to a Rule 10b5-1 trading plan adopted on September 12, 2025"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average sale price financial
"The price reported above reflects the weighted average sale price"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many HTFL shares did Campbell Rogers report selling?

111,412 shares were sold across transactions dated February 20 through November 17, 2026.

What price range applied to the February 20 HTFL sale?

The 16,918-share sale through The Campbell Rogers Revocable Trust was executed in multiple trades at $22.46 to $26.55; the reported weighted average sale price was $24.40 per share.

What holding is listed for CR Asset Protection Trust of 2023?

A holding entry lists 46,159 common shares for CR Asset Protection Trust of 2023, dated November 17, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Rogers Campbell

(Last)(First)(Middle)
C/O HEARTFLOW, INC.
135 MAIN STREET, SUITE 1000

(Street)
SAN FRANCISCO CALIFORNIA 94105

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Heartflow, Inc. [ HTFL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Medical Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/17/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock02/20/2026S(1)16,918D$24.4(2)33,836IBy The Campbell Rogers Revocable Trust
Common Stock03/19/2026S(1)16,918D$2516,918IBy The Campbell Rogers Revocable Trust
Common Stock04/01/2026S(1)16,918D$24.670IBy The Campbell Rogers Revocable Trust
Common Stock09/18/2026S(1)5,653D$50.1516,962IBy Campbell Rogers 2019 Irrevocable Trust
Common Stock09/18/2026S(3)6,503D$50.1519,509IBy Spouse's Trust
Common Stock10/22/2026S(3)5,654D$55.0111,308IBy Campbell Rogers 2019 Irrevocable Trust
Common Stock10/22/2026S(3)6,503D$55.0113,006IBy Spouse's Trust
Common Stock11/17/2026M(4)12,328A$8.3383,511D
Common Stock11/17/2026M(4)5,101A$2.2288,612D
Common Stock11/17/2026S(5)24,188D$46.3964,424D
Common Stock11/17/2026S(6)5,654D$46.395,654IBy Campbell Rogers 2019 Irrevocable Trust
Common Stock11/17/2026S(3)6,503D$46.396,503IBy Spouse's Trust
Common Stock46,159IBy CR Asset Protection Trust of 2023
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option$8.3311/17/2026M(4)12,328 (7)02/28/2030Common Stock12,328$06,799D
Stock Option$2.2211/17/2026M(4)5,101 (8)07/10/2033Common Stock5,101$060,581D
Explanation of Responses:
1. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2025.
2. This transaction was executed in multiple trades at price ranging from $22.46 to $26.55. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
3. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 16, 2026
4. The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on June 16, 2026.
5. Includes the sale of 6,759 shares of common stock held and the option exercise and sale of 17,429 shares reported on this Form 4 that were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on June 16, 2026.
6. The option exercise and sale reported on this Form 4 were effected pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on June 16, 2026.
7. These stock options are fully exercisable.
8. The option vests and becomes exercisable in monthly installments until July 1, 2027, subject to continued service through the applicable vesting date.
/s/ Mhairi Jones, by power of attorney11/19/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading